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Background: Early-onset hip osteoarthritis is commonly seen in people undergoing hip arthroscopy and is associated
with increased pain, reduced ability to participate in physical activity, reduced quality of life and reduced range of
motion and muscle strength. Despite this, the efficacy of non-surgical interventions such as exercise therapies remains
unknown. The primary aim is to establish the feasibility of a phase III randomised controlled trial investigating a targeted
physiotherapy intervention for people with early-onset hip osteoarthritis. The secondary aims are to determine the size
of treatment effects of a physiotherapy intervention, targeted to improve hip joint range and hip-related symptoms in
early-onset hip osteoarthritis following hip arthroscopy, compared to a health-education control.
Methods: This protocol describes a randomised, assessor- and participant-blind, controlled clinical trial. We will include
20 participants who are (i) aged between 18 and 50 years; (ii) have undergone hip arthroscopy during the past six to
12 months; (iii) have early-onset hip osteoarthritis (defined as chondrolabral pathology) at the time of hip arthroscopy;
and (iv) experience hip-related pain during activities. Primary outcome will be the feasibility of a phase III clinical trial.
Secondary outcomes will be (i) perceived global change score; (ii) hip-related symptoms (measured using the Hip
disability and Osteoarthritis Outcome Score (HOOS) pain subscale, activity subscale, and sport and recreation subscale);
(iii) hip quality of life (measured using the HOOS quality of life subscale and International Hip Outcome tool; (iv) hip
muscle strength and (v) hip range of motion. The physiotherapy intervention is semi-standardised, including joint and
soft tissue mobilisation and stretching, hip and trunk muscle retraining and functional and activity-specific retraining
and education. The control intervention encompasses individualised health education, with the same frequency and
duration as the intervention. The trial primary end-point is the conclusion of the 12-week intervention, and follow-up
measures will be collected at the 12-week post-baseline assessment.
Discussion: The findings of this study will provide guidance regarding the feasibility of a full-scale phase III randomised
controlled trial, prior to its undertaking.
Trial registration: The trial protocol was registered with the Australian Clinical Trials Registry (number: 12614000426684)
on 17 April 2014.
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Hip pathology is a common cause of hip pain [1,2], and
is associated with considerable morbidity in people aged
between 18 and 50 years [3,4]. In recent years, arthroscopic
surgery has contributed to advancements in assessment
and management of hip pain [5]. Recently, the number
of hip arthroscopic procedures performed in the United
States [6-8], United Kingdom, Australia [9] and Asia
[10] has increased dramatically. In Australia, Medicare
data indicate that between 2010 and 2013 the number
of people undergoing hip arthroscopy increased by over
50% [9], while in the United States the rate of hip
arthroscopic surgery increased six-fold between 2006
and 2010 [7]. Despite good results at between five and
10 years post-arthroscopy years, those with osteoarthritis
(OA) at arthroscopy consistently report less favourable
outcomes when compared to those without OA [11]. In
addition, we recently observed that early-onset hip OA is
associated with worse outcomes in people who have
undergone hip arthroscopy [12].
Musculoskeletal conditions are second only to mental
and behavioural disorders, as global contributors to years
lived with disability [13]. Due to its negative impact on
individual functioning and health service expenditure, OA
has been designated a National Health priority area [14].
The hip joint is a common site for OA [15], affecting
approximately 12% of adults in the United Kingdom [16]
and the United States of America [17]. As there is no cure
for hip OA, the identification of non-surgical interven-
tions that can reduce the progression of hip-related symp-
toms is important, as this will reduce disease burden [18].
We recently reported that chondrolabral pathology, a
marker of early-onset hip OA, is common in people who
undergo hip arthroscopy for hip pain, and is associated
with worse pain, difficulty participating in physical activity
and reduced quality-of-life compared to healthy controls
[19]. Moreover, it appears that early onset hip OA has a
significant impact on young and middle-aged people being
able to participate in physical activities without difficulty,
which could ultimately lead to physical inactivity. Inactivity
is associated with adverse health outcomes, which include
type two diabetes, ischaemic heat disease, stroke, depres-
sion and certain cancers [20]. If the progression of hip OA
symptoms can be slowed in its early stages, people with hip
OA may participate in greater levels of physical activity,
limiting the public health burden of this disease [21,22].
A full-scale phase III randomised controlled trial (RCT)
is costly, and before undertaking such a study it is import-
ant to establish its feasibility [23,24]. In Australia, hip arth-
roscopy is mostly conducted in the private sector and
such patients may be unwilling to participate in an RCT.
In addition, no RCT examining the effects of a physiother-
apy intervention has been undertaken in this population,
and adherence with the intervention is unknown. Thetreatment algorithm has not been tested within the con-
straints of a clinical trial and the adverse events are not
known. Therefore, before committing to a full-scale RCT,
the feasibility of such a study should be established by
undertaking a phase II RCT [24].
The primary aim of this study is to establish the feasibility
of a phase III RCT investigating a targeted physiotherapy
intervention for people with early-onset hip OA. The sec-
ondary aims are to determine the size of treatment effects
of a physiotherapy intervention, targeted to improve hip
joint range and hip-related symptoms in early-onset hip
OA following hip arthroscopy, compared to a health-
education control.
Methods/Design
Experimental design
This protocol describes a randomised, assessor- and
participant–blind, controlled clinical trial conforming
to Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) [25] guidelines. The trial protocol
was registered with the Australian Clinical Trials Registry
(ACTR number: 12614000426684) on 17 April 2014.
Ethics approval was obtained through the University of
Queensland Medical Research Ethics Committee (number:
2013001553).
Participants
A total of 20 participants will be recruited through a
single orthopedic surgeon (MGP) in Hobart, Australia,
with extensive expertise in hip arthroscopy. This number
of participants was chosen in order to determine the
feasibility of recruitment into a larger scale phase III trial,
as we estimate that 20 participants represents 30% of
eligible patients from a single surgeon. In addition, 20
participants will allow for observation of sample variability
and any possible adverse responses to the intervention. A
project investigator (KM) will screen for eligibility based
on history and examination.
Inclusion criteria
The inclusion criteria are as follows: (i) aged between 18
and 50 years; (ii) arthroscopy for intra-articular hip path-
ology during the past six to 12 months; (iii) evidence of
early-onset hip OA (defined as chondrolabral pathology)
at time of hip arthroscopy; (iv) hip-related pain during
activities such as sitting, squatting, stair ambulation or
twisting on the leg and (v) hip-related pain score of over
30 on a 100 mm visual analogue scale (VAS).
Exclusion criteria
The exclusion criteria are as follows: (i) pain that is not
confirmed by physical examination of the hip [26,27];
(ii) concurrent symptoms of hip bursitis or tendinitis;
(iii) surgical complications, including infection; (iv) planned
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arthroplasty); (v) physical inability to weight-bear fully or
undertake testing procedures and (vi) inability to under-
stand written and spoken English.
Procedure
Potential participants will be identified by the surgeon and
invited to contact the project coordinator (JK). (Figure 1)
The project coordinator will contact potential participants
by phone if they do not respond to the initial invitation.
Volunteers will be screened via telephone interview,
followed by a clinical examination to confirm eligibility
(KM). The randomisation schedule will be generated and
maintained centrally by the University of Queensland,
School of Health and Rehabilitation Sciences, and will be
revealed to the project coordinator (JK) via telephone
following the baseline assessment. The blinded researcher
(KM) will obtain informed consent (Additional file 1) and
will perform outcome assessments at baseline and three
months. Participants will be instructed not to divulge their
group allocation to the assessor. While physiotherapists
cannot be blinded to group allocation, participants will
be informed that they can receive one of two possible
interventions. Thus, participants will remain blinded to
treatment allocation. Participants will be asked to refrain
from other treatments, but stable drug doses will be per-
mitted. Physiotherapists will record per protocol treatment.
Participants will record adherence with home exercises,
adverse events and any co-interventions in a log book.
Outcome assessment
Outcomes will be assessed at baseline and at the trial
primary end-point, which is at the conclusion of the
12-week intervention.Figure 1 Flowchart of trial.Primary outcome measure: feasibility of a full-scale
randomized controlled trial
Feasibility will be assessed by evaluating the willingness of
participants to enrol; the number of eligible participants;
the recruitment rate; adherence to the intervention, home
exercises and log-book completion and the drop-out rate.
Adverse events will be recorded.
Secondary outcome measures: perceived global change score
Participants will rate their perceived change following
treatment on a six-point ordinal scale (completely recov-
ered, much improved, improved, no change, worse and
much worse) [28]. Measuring patient-perceived change
using such scales has been shown to be clinically relevant
and a stable concept for interpreting meaningful improve-
ments from an individual perspective [29].
Secondary outcome measure: hip-related symptoms
The Hip disability and Osteoarthritis Outcome Score
HOOS-pain [30] will measure hip-related symptoms. The
HOOS was evaluated in younger adults with OA [30], and
incorporates the Western Ontario MacMaster Universities
Osteoarthritis Index (WOMAC) 3.0LK [31]. The HOOS-
pain subscale is equivalent to the WOMAC pain subscale.
We have determined that the HOOS-pain subscale is reli-
able (intraclass correlation coefficient (ICC) = 0.96; 95%
confidence interval (CI): 0.93 to 0.98), with a low standard
error of measurement (SEM) of four points out of 100,
and is valid and responsive, with a minimal clinically
important change (MCIC) of nine points [32].
Secondary outcome measures: hip-related quality of life
The International Hip Outcome tool (iHOT-33) and
HOOS quality of life subscale (HOOS-Q) will measure
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score that was developed for specific use in the hip
arthroscopy population [33]. We determined that it is
reliable (ICC = 0.93; 95% CI: 0.87 to 0.96), with a low SEM
of six points out of 100, and is valid and responsive, with
an MCIC of 10 points [32]. The HOOS-Q [30] is reliable
(ICC = 0.95; 95% CI: 0.84 to 0.97), with a low SEM of five
points out of 100, and is valid and responsive, with an
MCIC of 11 points [32].
Secondary outcome measures: other hip-related symptoms
Other hip-related symptoms will include the HOOS
activity of daily living subscale (HOOS-A), the HOOS sport
and recreation subscale (HOOS-Sp) and HOOS symptoms
and stiffness subscale (HOOS-S). We determined these
subscales were reliable (ICC: 0.93 to 0.96), with low SEMs
of three to six points, and have MCICs ranging from six to
10 points [34].
Secondary outcome measures: hip muscle strength and
hip joint range
Hip abduction, extension and external rotation strength
and hip flexion range will be measured using our previously
published methods [35,36], with high reliability (ICC: 0.87
to 0.95). Briefly, all strength tests will be performed with a
Commander Power track II (J-Tech medical, Salt Lake City,
Utah, USA) hand-held dynamometer. The tester will match
the force generated by the participant performing an
isometric muscle contraction (the ‘make’ test) [37] and the
best of three tests will be recorded. Strength will be
recorded as a torque measure, calculated by multiplying
the force (measured in Newtons (N)) by the length of the
moment arm (measured in metres (m)), and then data will
be normalized for body weight (measured in kilograms
((kg) Nm/kg). Specifically, abductor strength will be
measured in the supine position, with stabilisation of the
contra-lateral thigh, and external rotation strength will be
measured in the prone position, with stabilisation of the
contra-lateral thigh [35]. Hip flexion range will be mea-
sured in the supine position as an active range of motion
measure, with stabilisation of the contra-lateral thigh.
It will be measured using a Plurimeter inclinometer
(Dr Rippstein, La Conversion, Switzerland) as the mean of
three measures [36].
Other measures
Potential covariates for statistical analyses
The potential covariates for statistical analyses are body
anthropometry: weight, height, body mass index and
waist girth.
Interventions
Each participant will be treated by experienced physio-
therapists who will be trained and proficient in bothinterventions (physiotherapy and control). The physio-
therapists will receive two training sessions prior to the
commencement of the study. Monthly meetings between
the treating physiotherapists and the project coordinator
(JK) will occur throughout the trial to ensure that the
physiotherapy intervention remains consistent. The
intervention is a face-to-face physiotherapy interven-
tion, which will be delivered in eight sessions over three
months (once per week for four weeks, then once per
fortnight for eight weeks). This semi-standardised type of
intervention has been described previously in an RCT
protocol for post-operative physiotherapy in patients with
femoro-acetabular impingement [38]. Participants will be
asked to refrain from other physiotherapy interventions
during the trial. All participants will be able to discuss
concerns regarding their condition with the project coord-
inator (JK) throughout the trial if needed.
Physiotherapy intervention Physiotherapy interventions
are detailed in Tables 1, 2 and Additional file 2. These
consist of (i) manual hip joint and soft tissue mobilisation
and stretching; (ii) hip muscle retraining; (iii) trunk muscle
retraining; (iv) functional, proprioceptive and sports- or
activity- specific retraining; (v) enhancing physical activity
and (vi) education. The treatment will be tailored ac-
cording to each patient’s clinical presentation (such as
strength, pain severity, sporting and functional needs),
the presence of co-morbidities (such as back and other
lower limb pain or pathology), and progressed based on
response to exercise load, thus maximising the training
effects. The physiotherapist will supervise exercises dur-
ing each visit. A home exercise program will be performed
independently at home four times per week. An exercise
manual will be made accessible to each participant.
Specific aspects of the treatment include:
1. Manual hip joint and soft tissue mobilisation and
stretching to provide optimal joint range and
facilitate control of movement patterns. Within
each treatment session, the therapist will measure
range of motion (with an inclinometer), and
monitor the immediate effects of treatment
modalities.
2. Hip muscle retraining, including exercise to improve
hip abduction, extension and external rotator
coordination and strength. In order to accommodate
a heterogeneous cohort, the hip muscle retraining
may be performed statically and/or dynamically in
various functional activities (for example, step up
and down, squat and/or sit to stand). Resistance will
be progressed based on individual responses, and is
detailed in Figure 2.
3. Trunk muscle retraining to improve strength,
endurance and control of the trunk muscles. The
Table 1 Manual therapy techniques: a semi-standardised approach
Manual therapy techniques
Technique Aim Description Dosage Timeframe
Soft tissue massage and trigger
point release of iliopsoas, adductor
group, gluteus minimus, gluteus
medius, piriformis and tensor
fascia latae
Address soft tissue restrictions
with the aim of reducing pain
and increasing hip joint range
of movement
Sustained digital pressure to
each trigger point, with the
muscle positioned on stretch
30 - 60 seconds digital
pressure per trigger point
Session 1 - 8
Massage longitudinally
along the muscle belly
2 - 5 minutes of
massage per muscle
Mobilisation of lumbar spine To improve lumbar spine
mobility and restore normal
lumbo-pelvic movement
Unilateral postero-anterior
accessory glides, Grade III or IV
3 - 5 sets of 30 - 60 seconds Session 1 - 8
Correction of sacro-iliac
joint asymmetries
To optimise the position of
the ilium and therefore the
orientation of the acetabulum
Massage to iliopsoas 2 - 5 minutes of massage Session 1 - 8
Mobilisation of sacrum
Manual traction if ligamentum
teres is intact or ligated and
patient is >3 months
post-labral repair
Increase hip flexion and/or
IR/ER range of motion
Seatbelt around patient's proximal
femur and therapist's hips. Gentle
inferior and/or lateral traction force
applied. May include patient
actively moving hip into flexion
as traction is applied
3 sets of 10 seconds. If
tolerated, increase by 1 set
per treatment session to a
maximum of 6 sets in total
Session 1 - 8
Legend: IR = internal rotation; ER = external rotation.
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principles to the hip muscle retraining.
4. Functional, proprioceptive and sports-specific
retraining. The exercise selection and progression will
follow similar principles to the hip and trunk muscle
retraining. For example, a person aiming to return to
football may perform single leg activities with
direction change and pain-free, graduated return to
kicking, whilst maintaining good movement control.
Control In order to control for the psychosocial contact
inherent with the physiotherapy treatment, the control
treatment will encompass individualised health education
sessions covering topics such as exercise, diet, weight loss
and appropriate stretching, in a similar fashion to previ-
ously published clinical trials looking at physiotherapyTable 2 Home exercise program for hip muscle retraining, tru
retraining and stretching: a semi-standardised approach
Home exercise program
Exercise Aim
Deep hip rotator strengthening Optimize hip neuromuscu
and improve dynamic stab
Hip extensor muscle strengthening Optimize hip neuromuscu
and improve dynamic stab
Hip abductor muscle strengthening Optimize hip neuromuscu
and improve dynamic stab
Functional strengthening Improve gluteal and lower
strength. Practice moveme
required for optimal daily
Balance exercises Improve proprioception an
stability of hip and pelvis
Anterior hip stretch Assist in regaining full hip
range of movementmanagement in older people with advanced hip OA
[39,40]. The information sheets have been modified to
be appropriate for this younger age group. The control
sessions will be provided with the same frequency and
duration as the physiotherapy sessions.
Data management, monitoring and statistical analyses
Treatment efficacy will be evaluated by comparing change
on primary outcome measures between groups. Baseline
characteristics of participating patients of the two groups
will be evaluated for their influence on outcomes and
included as covariates in statistical analyses if required.
Outcomes of interest will be analysed on an intention-to-
treat basis for all participants. SPSS software (Version 21,
SPSS Inc, Chicago, IL, USA) will be used for all analyses,
and significance will be set at P <0.05. Data monitoringnk muscle retraining, functional and activity specific
Description Timeframe
lar control
ility of hip
See Additional file 2 Session 1 - 4
lar control
ility of hip
See Additional file 2 Session 1 - 6
lar control
ility of hip
See Additional file 2 Session 2 - 8
limb
nt patterns
function
See Additional file 2 Session 3 - 8
d dynamic See Additional file 2 Session 2 - 8
extension See Additional file 2 Session 2 - 8
Figure 2 Examples of hip exercise progression from non-weight bearing to functional tasks.
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and data will be stored in a locked cabinet and password-
secured server. Adverse events will be recorded by the
treating physiotherapists who will inform the project
coordinator (JK). Trial results will be made available to
participants and will be published in a peer-reviewed
journal.
Consent
Written informed consent was obtained from the patients
for publication of this manuscript and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Discussion
This study provides detail of the protocol for a phase II
RCT investigating the efficacy of a physiotherapy interven-
tion for early-onset hip OA [24]. This phase II study will
identify the willingness of patients to enter a phase III RCT,
adherence to the interventions and possible drop-out rates.
In addition, this study will provide information regarding
the treatment effects sizes of the semi-individualised
physiotherapy intervention described, and assist in power
calculations which will inform future larger scale RCTs.
The physiotherapy intervention described herein is
semi-individualised, wherein a standardised program is
tailored to the individual patient’s needs, based on assess-
ment and reassessment undertaken at each physiotherapy
session. Impairments in hip range of motion and hip
muscle strength have been identified previously in people
with chondropathy of the hip [41]. Therefore we have in-
cluded therapeutic interventions targeted to address these
impairments in the physiotherapy intervention.
The control intervention is an alternative physiotherapy
intervention, focussing on education and guidance, rather
than a ‘wait and see’ control group. This will control for
both the attention and advice provided by physiotherapists
during individual treatment sessions and may facilitate
recruitment, since all patients will receive an active
intervention regardless of treatment allocation.
The findings of this study will provide guidance regard-
ing the feasibility of a full-scale phase III RCT, prior to itsundertaking [24]. It will also provide pilot data on the effi-
cacy of the physiotherapy intervention described herein.
Trial status
This trial is ongoing. At the time of submission of this
protocol, 17 patients had been recruited into the study
over a four-month recruitment period, and 16 patients
had completed the follow-up period. There have been
no reported adverse events, drop-outs or patients lost to
follow-up to date.
Additional files
Additional file 1: A randomized clinical trial of physiotherapy
intervention for early-onset hip osteoarthritis.
Additional file 2: Specific examples of exercises included in home
exercise program.
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